Bibliography

Download the OHTS Bibliography (pdf)

  1. Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group: The Ocular Hypertension Treatment Study: Design and Baseline Description of the Participants. Arch Ophthalmol 1999; 117:573-83. PMID: 10326953.
  2. Keltner JL, Johnson CA, Quigg JM, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. Confirmation of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2000; 118:1187-94. PMID: 10980763. View PowerPoint Presentation.
  3. Piltz J, Gross R, Shin DH, Beiser JA, Dorr DA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Contralateral Effect of Topical β-Adrenergic Antagonists in Initial One-eyed Trials in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2000; 130:441-53. PMID: 11024416.
  4. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Central Corneal Thickness in the Ocular Hypertension Treatment Study (OHTS). Ophthalmology 2001; 108:1779-88. PMID: 11581049. View PowerPoint Presentation.
  5. Feuer WJ, Parrish RK, II, Schiffman JC, Anderson DR, Budenz DL, Wells MC, Hess DJ, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Reproducibility of Cup/Disk Ratio Measurements Over Time at an Optic Disc Reading Center. Am J Ophthalmol 2002; 133:19-28. PMID: 11755836.
  6. Johnson CA, Keltner JL, Cello KE, Kass MA, Gordon MO, Budenz DL, Gaasterland DE, Werner E, and the Ocular Hypertension Study Group. Baseline Visual Field Characteristics in the Ocular Hypertension Treatment Study. Ophthalmology 2002; 109:432-7. PMID: 11874743.
  7. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish, RK, Wilson MR, Gordon MO for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: A Randomized Trial Determines That Topical Ocular Hypotensive Medication Delays or Prevents the Onset of Primary Open-Angle Glaucoma. Arch Ophthalmol 2002; 120:701-13. PMID: 12049574. View PowerPoint Presentation. [Editorial].
  8. Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Baseline Factors That Predict the Onset of Primary Open-Angle Glaucoma. Arch Ophthalmol 2002; 120:714-20. PMID: 12049575.
  9. Palmberg P. Answers From the Ocular Hypertension Treatment Study. Arch Ophthalmol. 2002 Jun;120(6):829-30. PMID: 1204959.
  10. Lee BL, Wilson MR; Ocular Hypertension Treatment Study (OHTS). Ocular Hypertension Treatment Study (OHTS) commentary. Curr Opin Ophthalmol. 2003 Apr;14(2):74-7. PMID: 12698045.
  11. Keltner JL, Johnson CA, Cello KE, Edwards MA, Bandermann SE, Kass MA, Gordon MO for the Ocular Hypertension Study Group. Classification of Visual Field Abnormalities in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2003; 121:643-50. PMID: 12742841.
  12. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Coleman AL, Piltz-Seymour JR, Liebmann JM, Cioffi GA, Trick G, Brandt JD, Gordon MO, Kass MA, for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Racial Differences in Optic Disc Topography: Baseline Results From the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2004; 122:22-8. PMID: 14718290.
  13. Zangwill LM, Weinreb RN, Berry CC, Smith AR, Dirkes KA, Liebmann JM, Brandt JD, Trick G, Cioffi GA, Coleman AL, Piltz-Seymour JR, Gordon MO, Kass MA and the OHTS CSLO Ancillary Study Group. The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study: Study Design and Baseline Factors. Am J Ophthalmol 2004; 137:219-27. PMID: 14962409. View PowerPoint Presentation.
  14. Robin AL, Frick KD, Katz J, Budenz D, Tielsch JM. The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease? Arch Ophthalmol. 2004 Mar;122(3):376-8. Review. Erratum in: Arch Ophthalmol. 2004 Jul;122(7):1039. PMID: 15006854.
  15. Jampel HD. We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study. Arch Ophthalmol. 2004 Mar;122(3):378-9. PMID: 15006855.
  16. Brandt JD. Corneal Thickness in Glaucoma Screening, Diagnosis, and Management. Curr Opin Ophthalmol. 2004 Apr;15(2):85-9. PMID: 15021216.
  17. Higginbotham EJ, Gordon MO, Beiser JA, Drake MV, Bennett GR, Wilson MR, Kass MA for the Ocular Hypertension Treatment Study Group. The Ocular Hypertension Treatment Study: Topical Medication Delays or Prevents Primary Open-angle Glaucoma in African American Individuals. Arch Ophthalmol 2004; 122:813-20. PMID: 15197055. View PowerPoint Presentation.
  18. Coleman AL, Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study (OHTS). Baseline Risk Factors for the Development of Primary Open-angle Glaucoma in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004; 138(4):684-5. PMID: 15488816.
  19. Brandt JD, Beiser JA, Gordon MO, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Central Corneal Thickness and Measured IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study. Am J Ophthalmol 2004; 138:717-22. PMID: 15531304.
  20. Kass MA, Gordon MO, Kymes SM for the Ocular Hypertension Treatment Study (OHTS) Group. Incorporating the Results of the Ocular Hypertension Treatment Study Into Clinical Practice. Letter to Editor. Arch Ophthalmol 2005; 123:1021-2. PMID: 16009857.
  21. Zangwill LM, Weinreb RN, Beiser JA, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO for the Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study Group. Baseline Topographic Optic Disc Measurements are Associated With the Development of Primary Open-Angle Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005; 123:1188-97. PMID: 16157798. View PowerPoint Presentation.
  22. Keltner JL, Johnson CA, Levine RA, Fan JJ, Cello KE, Kass MA, Gordon MO for the Ocular Hypertension Treatment Study Group. Normal Visual Field Test Results Following Glaucomatous Visual Field End Points in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2005; 123:1201-6. PMID: 16157799. PMCID: PMC1828122.
  23. Medeiros FA, Weinreb RN, Sample PA, Gomi CF, Bowd C, Crowston JG, Zangwill LM. Validation of a Predictive Model to Estimate the Risk of Conversion From Ocular Hypertension to Glaucoma. Arch Ophthalmol. 2005 Oct;123(10):1351-60. PMID: 16219726.
  24. Parrish RK, Schiffman JC, Feuer WJ, Anderson DR, Budenz DL, Wells-Albornoz M-C, Vandenbroucke R, Kass MA, Gordon MO, and the Ocular Hypertension Treatment Study Group. Test-retest Reproducibility of Optic Disk Deterioration Detected From Stereophotographs by Masked Graders. Am J Ophthalmol 2005; 140:762-4. PMID: 16226544. View PowerPoint Presentation.
  25. Kymes SM, Kass MA, Anderson DR, Miller JP, Gordon MO, and the Ocular Hypertension Treatment Study Group (OHTS). Management of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006; 141:997-1008. PMID: 16765666. PMCID: PMC1775049.
  26. Higginbotham EJ. Treating Ocular Hypertension to Reduce Glaucoma Risk: When to Treat? Drugs. 2006;66(8):1033-9. PMID: 16789790.
  27. Herman DC, Hodge DO, Bourne, WM. Changes in the Corneal Thickness in Patients With Treated and Untreated Ocular Hypertension. Cornea 2006; 25:639-43. PMID: 17077653.
  28. Levine RA, Demirel S, Fan J, Keltner JL, Johnson CA, Kass MA and the Ocular Hypertension Treatment Study Group. Asymmetries and Visual Field Summaries as Predictors of Glaucoma in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2006; 47:3896-903. PMID: 16936102. PMCID: PMC1995656.
  29. Keltner JL, Johnson CA, Anderson DR, Levine RA, Fan JJ, Cello KE, Quigley HA, Budenz DL, Parrish II RK, Kass MA, Gordon MO, Ocular Hypertension Treatment Study Group. The Association between Glaucomatous Visual Fields and Optic Nerve Head Features in the Ocular Hypertension Treatment Study. Ophthalmology 2006; 113(9):1603-12. PMID: 16949445. PMCID: PMC1995656.
  30. Baratz KH, Nau CB, Winter EJ, McLaren JW, Hodge DO, Herman DC, Bourne WM. Effects of Glaucoma Medications on Corneal Endothelium, Keratocytes, and Subbasal Nerves Among Participants in the Ocular Hypertension Treatment Study. Cornea 2006; 25:1046-52. PMID:17133051.
  31. Mansberger SL, Cioffi GA. The Probability of Glaucoma From Ocular Hypertension Determined by Ophthalmologists in Comparison to a Risk Calculator. J Glaucoma. 2006 Oct;15(5):426-31. PMID: 16988606.
  32. Herman DC, Gordon MO, Beiser JA, Chylack Jr. LT, Lamping KA, Schein OD, Soltau JB, Kass MA, and the Ocular Hypertension Treatment Study (OHTS) Group. Topical Ocular Hypotensive Medication and Lens Opacification: Evidence From the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006; 142:800-10. PMID: 17056362. PMCID: PMC1976472. View PowerPoint Presentation.
  33. Budenz DL, Anderson DR, Feuer WJ, Beiser JA, Schiffman J, Parrish II RK, Piltz-Seymour JR, Gordon MO, Kass MA, Ocular Hypertension Treatment Study Group. Detection and Prognostic Significance of Optic Disc Hemorrhages During the Ocular Hypertension Treatment Study. Ophthalmology 2006; 113(12):2137-43. PMID: 16996592. PMCID: PMC1995568. View PowerPoint Presentation.
  34. Ocular Hypertension Treatment Study (OHTS) Group, European Glaucoma Prevention Study Group. Validated Prediction Model for the Development of Primary Open-Angle Glaucoma in Individuals with Ocular Hypertension. Ophthalmology 2007; 114(1):10-9. PMID: 17095090. PMCID: PMC1995665. View PowerPoint Presentation.
  35. Mansberger SL, Hughes BA, Gordon MO, Spaner SD, Beiser JA, Cioffi GA, Kass MA and the Ocular Hypertension Treatment Study (OHTS) Group. Comparison of Initial Intraocular Pressure Response With Topical β-Adrenergic Antagonists and Prostaglandin Analogues in African American and White Individuals in the Ocular Hypertension Treatment Study. Archives of Ophthalmology 2007; 125(4):454-9. PMID: 17420364.
  36. Brandt JD. Central Corneal Thickness, Tonometry, and Glaucoma Risk–A Guide for the Perplexed. Can J Ophthalmol. 2007 Aug;42(4):562-6. PMID: 17641698.
  37. Keltner JL, Johnson CA, Cello KE, Bandermann SE, Fan JJ, Levine RA, Kass MA, Gordon MO and the Ocular Hypertension Treatment Study Group. Visual Field Quality Control in the Ocular Hypertension Treatment Study (OHTS). J Glaucoma 2007; 16:665-9. PMID: 18091452.
  38. Gordon MO, Beiser JA, Kass MA for the Ocular Hypertension Treatment Study Group. Is a History of Diabetes Mellitus Protective Against Developing Primary Open-angle Glaucoma? Arch Ophthalmol 2008; 126:280-2. PMID: 18268230. View PowerPoint Presentation.
  39. Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. Diabetes and Glaucoma. Arch Ophthalmol 2008;126(5):746-a-7. PMID: 18474807.
  40. Brandt JD, Gordon MO, Beiser JA, Lin SC, Alexander MY, Kass MA, Ocular Hypertension Treatment Study Group. Changes in Central Corneal Thickness over Time: The Ocular Hypertension Treatment Study. Ophthalmology 2008; 115:1550-6. PMID: 18378313.
  41. The Ocular Hypertension Treatment Group and the European Glaucoma Prevention Study Group. The Accuracy and Clinical Application of Predictive Models for Primary Open-Angle Glaucoma in Ocular Hypertensive Individuals. Ophthalmology 2008; 115(11):2030-6. PMID: 18801578. PMCID: PMC3117658.
  42. Boland MV, Quigley HA, Lehmann HP. The Impact of Risk Calculation on Treatment Recommendations Made by Glaucoma Specialists in Cases of Ocular Hypertension. J Glaucoma. 2008 Dec;17(8):631-8. PMID: 19092458.
  43. Higginbotham EJ. Ocular Hypertension Treatment Study. Arch Ophthalmol. 2009 Feb;127(2):213-5. PMID: 19204243.
  44. Bhorade AM, Gordon MO, Wilson B, Weinreb RN, Kass MA, for the Ocular Hypertension Treatment Study Group. Variability of Intraocular Pressure Measurements in Observation Participants in the Ocular Hypertension Treatment Study. Ophthalmology 2009;116:717-24. PMID: 19243824. PMCID: PMC2790916. View PowerPoint Presentation.
  45. Kass MA, Gordon MO, Gao F, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JK, Miller JP, Parrish RK, Wilson MR, for the Ocular Hypertension Treatment Study Group. Delaying Treatment of Ocular Hypertension. Arch Ophthalmol 2010;128(3):276-87. PMID: 20212196. PMCID: PMC3966140. View PowerPoint Presentation.
  46. Barnett EM, Fantin A, Wilson BS, Kass MA, Gordon MO, for the Ocular Hypertension Treatment Study Group. The Incidence of Retinal Vein Occlusion in the Ocular Hypertension Treatment Study. Ophthalmology 2010;117(3):484-8. PMID: 20031222. PMCID: PMC3077045.
  47. Kymes SM, Plotzke MR, Kass MA, Boland MV, Gordon MO. Effect of Patient’s Life Expectancy on the Cost-effectiveness of Treatment for Ocular Hypertension. Arch Ophthalmol 2010;128(5):613-8. PMID: 20457984. PMCID: PMC4010144.
  48. Weinreb RN, Zangwill LM, Jain Sonia, Becerra LM, Dirkes Keri, Piltz-Seymour JR, Cioffi GA, Trick GL, Coleman AL, Brandt JD, Liebmann JM, Gordon MO, Kass MA, for the OHTS CSLO Ancillary Study Group. Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Ophthalmology 2010;117(9):1674-83. PMID: 20633931. PMCID: PMC3938159.
  49. Bhorade AM, Wilson BS, Gordon MO, Palmberg P, Weinreb RN, Miller E, Chang RT, Kass MA, for the Ocular Hypertension Treatment Study Group. The Utility of the Monocular Trial: Data from the Ocular Hypertension Treatment Study. Ophthalmology 2010;117(11):2047-54. PMID: 20619460. PMCID: PMC2955184.
  50. Artes PH, Chauhan BC, Keltner JL, Cello KE, Johnson CA, Anderson DR, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Group. Longitudinal and Cross-sectional Analyses of Visual Field Progression in Participants of the Ocular Hypertension Treatment Study. Arch Ophthalmol 2010;128(12):1528-32. PMID: 21149774. PMCID: PMC3914151.
  51. Gao F, Miller JP, Xiong C, Beiser JA, Gordon MO, and the Ocular Hypertension Treatment Study (OHTS) Group. A Joint-modeling Approach to Assess the Impact of Biomarker Variability on the Risk of Developing Clinical Outcome. Statistical Methods & Applications 2011;20(1):83-100. PMID: 21339862. PMCID: PMC3039885.
  52. Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA. A joint Model for Prognostic Effect of Biomarker Variability on Outcomes: Long-term Intraocular Pressure (IOP) Fluctuation on the Risk of Developing Primary Open-Angle Glaucoma (POAG). JP Journal of Biostatistics 2011 May 1;5(2) 73-96. PMID: 22180704. PMCID: PMC3237682.
  53. Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA. The 10-Year Incidence of Glaucoma Among Patients With Treated and Untreated Ocular Hypertensive. Arch Ophthalmol 2011;129(12):1630-1. PMID: 22159688.
  54. Demirel S, De Moraes CG, Gardiner SK, Liebmann JM, Cioffi GA, George R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study. The Rate of Visual Field Change in the Ocular Hypertension Treatment Study. Invest Ophthalmol Vis Sci 2012;53(1)224-7. PMID: 22159015. PMCID: PMC3292359.
  55. Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP, Kass MA, for the Ocular Hypertension Treatment Study Group. Adjusting Intraocular Pressure for Central Corneal Thickness Does Not Improve Prediction Models for Primary Open-Angle Glaucoma. Ophthalmology 2012;119(3):437-42. PMID: 21705084. PMCID: PMC3184359.
  56. De Moraes CG, Demirel S, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. Effect of Treatment on the Rate of Visual Field Change in the Ocular Hypertension Treatment Study Observation Group. Invest Ophthalmol Vis Sci 2012;53:1704-9. PMID: 22395889. PMCID: PMC3342789.
  57. Kymes SM, Lambert DL, Lee PP, Musch DC, Siegfried CJ, Kotak SV, Stwalley DL, Fain J, Johnson C, Gordon MO. The Development of a Decision Analytic Model of Changes in Mean Deviation in People with Glaucoma. Ophthalmology 2012;119:1367-74. PMID: 22537616. PMCID: PMC3389134.
  58. Mansberger SL, Gordon MO, Jampel H, Bhorade A, Brandt JD, Wilson B, Kass MA, for the Ocular Hypertension Treatment Study Group. Reduction in Intraocular Pressure after Cataract Extraction: The Ocular Hypertension Treatment Study. Ophthalmology 2012;119:1826-31. PMID: 22608478. PMCID: PMC3426647.
  59. Gao F, Miller JP, Miglior S, Beiser JA, Torri V, Kass MA, Gordon MO. The Effect of Changes in Intraocular Pressure on the Risk of Primary Open-angle Glaucoma in Patients with Ocular Hypertension: An Application of Latent Class Analysis. BMC Med Res Methodol. 2012 Oct 4;12:151. PMID: 23035867. PMCID: PMC3532135.
  60. De Moraes CG, Demirel S, BScOptom, Gardiner SK, Liebmann JM, Cioffi GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. Rate of Visual Field Progression in Eyes With Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. Arch Ophthalmol 2012;130:1541-46. PMID: 22892940.
  61. Gardiner SK, Demirel S, De Moraes CG, Liebmann JM, Cioffi, GA, Ritch R, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. Series Length used during Trend Analysis Affects Sensitivity to Changes in Progression Rate in the Ocular Hypertension Treatment Study (OHTS). Invest Ophthalmol Vis Sci. 2013;54(2): 1252–9. PMID 23349433. PMCID: PMC3597197.
  62. Gardiner SK, Demirel S, Gordon MO, Kass MA, for the Ocular Hypertension Treatment Study Group. Seasonal Changes in Visual Field Sensitivity and Intraocular Pressure in the Ocular Hypertension Treatment Study. Ophthalmology 2013 Apr;120(4):724-30. PMID: 23357622. PMCID: PMC3618610.
  63. Zangwill LM, Jain S, Dirkes K, He F, Medeiros FA, Trick GL, Brandt JD, Cioffi GA, Coleman AL, Liebmann JM, Piltz-Seymour JR, Gordon MO, Kass MA, Weinreb RN; Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. The Rate of Structural Change: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Am J Ophthalmology 2013;155(6):971–82. PMID: 23497845. PMCID: PMC4310682.
  64. Savatovsky E, Mwanza JC, Budenz DL, Feuer WJ, Vandenbroucke R, Schiffman JC, Anderson DR; Ocular Hypertension Treatment Study Longitudinal changes in peripapillary atrophy in the ocular hypertension treatment study: a case-control assessment. Ophthalmology 2015 Jan;122(1):79-86. PMID: 25208858. PMCID: PMC4682350.
  65. Christopher M, Abràmoff MD, Tang L, Gordon MO, Kass MA, Budenz DL, Fingert JH, Scheetz TE. Stereo Photo Measured ONH Shape Predicts Development of POAG in Subjects With Ocular Hypertension. Invest Ophthalmol Vis Sci. 2015 Jul 1;56(8):4470-9. PMID: 26193923. PMCID: PMC4509059.
  66. Feng Gao, J Philip Miller, Julia A Beiser, Chengjie Xiong, Mae O Gordon. Predicting Clinical Binary Outcome Using Multivariate Longitudional Data: Application to Patients with Newly Diagnosed Primary Open – Angle Glaucoma. J Biom Biostat 6:254. PMID: 26904374. PMCID: PMC4760987.
  67. Schaefer JL, Lukowski ZL, Meyer AM, Leoncavallo AJ, Greer A, Martorana GM, Zou B, Shuster JJ, Sherwood MB. Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Software Program in Ophthalmologists-in-Training. Am J Ophthalmol. 2016 Jul;167:88-95. PMID: 27038890. PMCID: PMC5697426.
  68. Scheetz TE, Faga B, Ortega L, et al. Glaucoma Risk Alleles in the Ocular Hypertension Treatment Study. Ophthalmology 2016;123(12):2527-36. PMID: 27707548. PMCID: PMC5121091.
  69. Khawaja AP, Cooke Bailey JN, et al. Assessing the Association of Mitochondrial Genetic Variation With Primary Open-Angle Glaucoma Using Gene-Set Analyses. Invest Ophthalmol Vis Sci. 2016 Sep; 57(11): 5046–5052. PMID: 27661856. PMCID: PMC5040191.
  70. Bailey JN, Loomis SJ, et al. Genome-wide association analysis identifies TXNRD2, ATXN2 and FOXC1 as susceptibility loci for primary open angle glaucoma. Nat Genet. 2016 Feb; 48(2): 189–194. PMID: 26752265. PMCID: PMC4731307.
  71. Budenz DL, Huecker JB, Gedde SJ, Gordon M, Kass M, Ocular Hypertension Treatment Study. Thirteen-Year Follow-up of Optic Disc Hemorrhages in the Ocular Hypertension Treatment Study. Am J Ophthalmol. Feb 2017;174:126-133. PMID: 27832941. PMCID: PMC5658027.
  72. Jamie L Schaefer, Alissa M Meyer,Cooper D Rodgers,Nicole C Rosenberg, Anthony J Leoncavallo, Zachary L Lukowski, Anthony B Greer, Gina M Martorana, Baiming Zou, Jonathan J Shuster, L Jay Katz, Joel S Schuman, Michael A Kass, Mark B Sherwood. Comparing Glaucomatous Disc Change Using Stereo Disc Viewing and the MatchedFlicker Programme in Glaucoma Experts and Trainees. Br J Ophthalmol. 2018 Mar;102(3):358-363. PMID: 28814418.
  73. Gao F, Philip Miller J, Xiong C, Luo J, Beiser JA, Chen L, Gordon MO. Estimating Correlation Between Multivariate Longitudinal Data in the Presence of Heterogeneity. BMC Med Res Methodol. 2017 Aug 17;17(1):124. PMID: 28818061. PMCID: PMC5561646.
  74. Chen Z, Wang K. A Gene-based Test of Association Through an Orthogonal Decomposition of Genotype Scores. Hum Genet. 2017 Oct;136(10):1385-1394. PMID: 28864915.
  75. Wang K. Conditional Asymptotic Inference for the Kernel Association Test. Bioinformatics. 2017 Dec 1;33(23):3733-3739. PMID: 28961861. PMCID: PMC5860324.
  76. Gordon MO, Kass MA. What We Have Learned From the Ocular Hypertension Treatment Study. Am J Ophthalmol. 2018 May;189:xxiv-xxvii. PMID: 29501371. PMCID: PMC5915899.